Sort
16,300 grants matching “fatty liver disease”
FATTY ACID TRANSPORTER: REGULATION, IDENTIFICATION
$339,034Nada A. Abumrad · Washington University · R01 · FY2014 · DK
Hepatic mitochondrial oxidative stress, AIDS and alcohol
$339,030Emory University · R01 · FY2005 · AA
The Role of O-Glycosylation on the InsP3R in Liver Metabolism
$339,027Barbara E. Ehrlich · Yale University · P01 · FY2011 · DK
Role of NCOA5 in hepatic steatosis and hepatocarcinogenesis
$339,023Hua Xiao · Michigan State University · R01 · FY2016 · CA
APO B TRANSLOCATION AND DEGRADATION
$338,981San Diego State University · R01 · FY2002 · HL
PPAR Delta Functions in Liver
$338,969Chih-Hao Lee · Harvard School Of Public Health · R01 · FY2013 · DK
Optimizing medium-chain lipids for the treatment of long-chain fatty acid oxidation disorders
$338,958Eric S Goetzman · University Of Pittsburgh At Pittsburgh · R01 · FY2023 · HD
Project 4: The Role of Reactive Oxygen Species and the Microbiome in Toxicant Induced Liver Fibrosis
$338,844David A Brenner · University Of California, San Diego · P42 · FY2019 · ES
Cefalu: Core 2; Integrative Biology Core (Mynatt)
$338,817Randall Lee Mynatt · Lsu Pennington Biomedical Research Ctr · P50 · FY2017 · AT
Cefalu: Core 2; Integrative Biology Core (Mynatt)
$338,817Randall Lee Mynatt · Lsu Pennington Biomedical Research Ctr · P50 · FY2019 · AT
Impact of FGF21-mediated immune-metabolic interactions on immune-senescence
$338,739Vishwa Deep Dixit · Yale University · P01 · FY2017 · AG
Hyperhomocysteinemia, S-adenosylhomocysteine Accumulation, and Epigenetics
$338,676Warren D Kruger · Fox Chase Cancer Center · R01 · FY2012 · GM
Effects of ethanol on AMP kinase signaling
$338,625Indiana Univ-Purdue Univ At Indianapolis · R01 · FY2004 · AA
Endocrine disruptor mediated activation of PXR causes dyslipidemia
$338,625Changcheng Zhou · University Of Kentucky · R01 · FY2017 · ES
Gut Inflammation from Emulsifier Perturbations of Microbiota-Host Interactions
$338,625Andrew T Gewirtz · Georgia State University · R01 · FY2015 · DK
Endocrine disruptor mediated activation of PXR causes dyslipidemia
$338,625Changcheng Zhou · University Of Kentucky · R01 · FY2015 · ES
Effects of ethanol on AMP kinase signaling
$338,625Indiana Univ-Purdue Univ At Indianapolis · R01 · FY2005 · AA
Endocrine disruptor mediated activation of PXR causes dyslipidemia
$338,625Changcheng Zhou · University Of Kentucky · R01 · FY2016 · ES
Mass Spectrometry Strategies to Identify Lipid Biomarkers of Disease
$338,580Gavin Edmund Reid · Michigan State University · R01 · FY2010 · RR
Regulation of hepatic lipid metabolism by a novel Foxo pathway
$338,575Xiaocheng Charlie Dong · Indiana University Indianapolis · R01 · FY2012 · DK
Pre-clinical Testing of a Novel Therapeutic for Nonalcoholic Steatohepatitis
$338,549Joel Thomas Dudley · Icahn School Of Medicine At Mount Sinai · UH2 · FY2017 · TR
Role of NCOA5 in hepatic steatosis and hepatocarcinogenesis
$338,538Hua Xiao · Michigan State University · R01 · FY2017 · CA
Serotonergic antidepressants as liver tumor preventives
$338,378Kimberley Jane Evason · University Of Utah · R01 · FY2019 · CA
CORE--Clinical Core
$338,360Kitt F Petersen · Yale University · P01 · FY2007 · DK
Function and Mechanism of DDB1-CUL4A E3 Ligase in Liver Lipid Metabolism
$338,213Lei Yin · University Of Michigan At Ann Arbor · R01 · FY2014 · DK